【带你探索】罗氟司特薄膜片(Daxas)生产厂家

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease. Under the influence of airflow limitation, gas is excessively retained in the lungs of COPD patients during exhalation, which in turn causes patients to have difficulty breathing, decreased exercise tolerance, worsened quality of life, and increased risk of death. Among men over 40 years old, the incidence of chronic obstructive pulmonary disease is higher, and smoking has become a major risk factor. The rate of clinical missed diagnosis and misdiagnosis of COPD has reached as high as 70%, and it is currently one of the five leading causes of death in humans. It is the first new oral drug approved for COPD worldwide. On July 6, 2010, the European Union approved the marketing of Nycomed's roflumilast tablets for auxiliary bronchodilator maintenance treatment in patients with severe COPD. On March 1, 2011, the U.S. Food and Drug Administration (FDA) approved Roflumilast tablets for the treatment of severe COPD patients with chronic bronchitis and a history of exacerbations to reduce the risk of COPD exacerbations in these patients.

Roflumilast is an oral preparation that is mainly expressed on inflammatory cells related to asthma, including eosinophils, neutrophils and mast cells. The drug can specifically act on a certain enzyme involved in smooth muscle contraction, thereby blocking the transmission of pro-inflammatory response signals. It has anti-inflammatory activity and has achieved good results in the clinical treatment of asthma and COPD. Smooth muscle contraction is one of the hallmarks of bronchospasm, a sudden narrowing of the airways that can cause breathing difficulties and respiratory diseases. Roflumilast also significantly delayed the worsening of respiratory symptoms and improved patients' quality of life.

Roflumilast film tablets (Daxas) manufacturer:

Roflumilast was first developed by the German company Altana and is now a product of the Swiss Nycomed GmbH.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: